Barclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)

Barclays PLC lifted its stake in Capricor Therapeutics Inc (NASDAQ:CAPR) by 106.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,296 shares of the biotechnology company’s stock after buying an additional 18,724 shares during the period. Barclays PLC owned approximately 0.08% of Capricor Therapeutics worth $552,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in Capricor Therapeutics in the 3rd quarter valued at $133,000. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the second quarter valued at about $147,000. The Manufacturers Life Insurance Company acquired a new position in Capricor Therapeutics in the third quarter valued at about $161,000. Sassicaia Capital Advisers LLC bought a new stake in Capricor Therapeutics during the third quarter worth about $192,000. Finally, BNP Paribas Financial Markets grew its stake in Capricor Therapeutics by 868.7% during the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after buying an additional 15,872 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $13.70 on Friday. Capricor Therapeutics Inc has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The stock has a market cap of $622.94 million, a PE ratio of -12.92 and a beta of 4.08. The firm’s fifty day moving average price is $15.46 and its two-hundred day moving average price is $11.50.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CAPR shares. Oppenheimer restated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald boosted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler started coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Maxim Group lifted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, HC Wainwright restated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.